Form D · Biotechnology

Therabron Therapeutics, Inc.

Rockville, MD · CIK 0001505318

Offering snapshot reported Dec 27, 2016 · SEC filing

Reported sold
$2.33M
Offering amount: $6.05M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 12, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 27, 2016Initial$2,325,000No comparison4SEC filing
Nov 18, 2015Initial$5,500,000No comparison1SEC filing
Jun 17, 2014Initial$7,180,523No comparison11SEC filing
Sep 18, 2012Initial$250,000No comparison1SEC filing
Nov 10, 2011Amendment$315,000$275,000vs Nov 10, 20105SEC filing
Nov 10, 2010Initial$40,000No comparison1SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-277047
The underlying shares of common stock issuable upon conversion thereof.

Source: Form D, filed Dec 27, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Todd Brady Director
Linda Chang Executive
Christine Copple Director
Blanche M Johnson Director
Thomas Miller Executive
Aprile L Pilon Clayton Director, Executive
Vinzenz Ploerer Director, Executive
Eric Richman Director
Jeffrey M Zell Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9430 Key West Avenue, Suite 150
Rockville, MD, 20850